These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 22819924)

  • 1. Structural mass spectrometry in biologics discovery: advances and future trends.
    Mo J; Tymiak AA; Chen G
    Drug Discov Today; 2012 Dec; 17(23-24):1323-30. PubMed ID: 22819924
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of protein therapeutics by mass spectrometry: recent developments and future directions.
    Chen G; Warrack BM; Goodenough AK; Wei H; Wang-Iverson DB; Tymiak AA
    Drug Discov Today; 2011 Jan; 16(1-2):58-64. PubMed ID: 21093608
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-resolution MS for structural characterization of protein therapeutics: advances and future directions.
    Wei H; Tymiak AA; Chen G
    Bioanalysis; 2013 May; 5(10):1299-313. PubMed ID: 23721450
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hydrogen-deuterium exchange mass spectrometry for determining protein structural changes in drug discovery.
    Lee JJ; Park YS; Lee KJ
    Arch Pharm Res; 2015 Oct; 38(10):1737-45. PubMed ID: 25743629
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Higher order structure characterization of protein therapeutics by hydrogen/deuterium exchange mass spectrometry.
    Huang RY; Chen G
    Anal Bioanal Chem; 2014 Oct; 406(26):6541-58. PubMed ID: 24948090
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hydrogen deuterium exchange mass spectrometry in biopharmaceutical discovery and development - A review.
    Deng B; Lento C; Wilson DJ
    Anal Chim Acta; 2016 Oct; 940():8-20. PubMed ID: 27662755
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Utilization of Hydrogen/Deuterium Exchange in Biopharmaceutical Industry].
    Coufalová D; Vojtěšek B; Hernychova L
    Klin Onkol; 2016; 29 Suppl 4(Suppl 4):59-63. PubMed ID: 27846722
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hydrogen exchange mass spectrometry for studying protein structure and dynamics.
    Konermann L; Pan J; Liu YH
    Chem Soc Rev; 2011 Mar; 40(3):1224-34. PubMed ID: 21173980
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hydrogen deuterium mass spectrometry in drug discovery.
    Campobasso N; Huddler D
    Bioorg Med Chem Lett; 2015 Sep; 25(18):3771-6. PubMed ID: 26189895
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hydrogen/deuterium exchange mass spectrometry for probing higher order structure of protein therapeutics: methodology and applications.
    Wei H; Mo J; Tao L; Russell RJ; Tymiak AA; Chen G; Iacob RE; Engen JR
    Drug Discov Today; 2014 Jan; 19(1):95-102. PubMed ID: 23928097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent advancements in mass spectrometry for higher order structure characterization of protein therapeutics.
    Chen G; Tao L; Li Z
    Drug Discov Today; 2022 Jan; 27(1):196-206. PubMed ID: 34571276
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Getting to the core of protein pharmaceuticals--Comprehensive structure analysis by mass spectrometry.
    Leurs U; Mistarz UH; Rand KD
    Eur J Pharm Biopharm; 2015 Jun; 93():95-109. PubMed ID: 25791210
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Applications of LC/MS in structure identifications of small molecules and proteins in drug discovery.
    Chen G; Pramanik BN; Liu YH; Mirza UA
    J Mass Spectrom; 2007 Mar; 42(3):279-87. PubMed ID: 17295416
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HDX-MS guided drug discovery: small molecules and biopharmaceuticals.
    Marciano DP; Dharmarajan V; Griffin PR
    Curr Opin Struct Biol; 2014 Oct; 28():105-11. PubMed ID: 25179005
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mass spectrometry combined with oxidative labeling for exploring protein structure and folding.
    Konermann L; Stocks BB; Pan Y; Tong X
    Mass Spectrom Rev; 2010; 29(4):651-67. PubMed ID: 19672951
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peptide and protein drug analysis by MS: challenges and opportunities for the discovery environment.
    Campbell JL; Le Blanc JC
    Bioanalysis; 2011 Mar; 3(6):645-57. PubMed ID: 21417733
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mass spectrometry based tools to investigate protein-ligand interactions for drug discovery.
    Pacholarz KJ; Garlish RA; Taylor RJ; Barran PE
    Chem Soc Rev; 2012 Jun; 41(11):4335-55. PubMed ID: 22532017
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison of mass spectrometry based hydrogen deuterium exchange methods for probing the cyclophilin A cyclosporin complex.
    Esswein ST; Florance HV; Baillie L; Lippens J; Barran PE
    J Chromatogr A; 2010 Oct; 1217(43):6709-17. PubMed ID: 20557890
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The utility of hydrogen/deuterium exchange mass spectrometry in biopharmaceutical comparability studies.
    Houde D; Berkowitz SA; Engen JR
    J Pharm Sci; 2011 Jun; 100(6):2071-86. PubMed ID: 21491437
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Native MS: an 'ESI' way to support structure- and fragment-based drug discovery.
    Vivat Hannah V; Atmanene C; Zeyer D; Van Dorsselaer A; Sanglier-Cianférani S
    Future Med Chem; 2010 Jan; 2(1):35-50. PubMed ID: 21426045
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.